Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, announced the publication of a scientific paper entitled, “The Novel Reversible LSD1 Inhibitor SP-2577 Promotes Anti-Tumor Immunity ...

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, referred to as epigenetics, has announced that its chief executive officer, David Arthur, will present at the Biotech Showcase 2020 ...

The call featured a presentation and discussion by Key Opinion Leaders (KOLs) Damen Reed, MD (Moffitt Cancer Center) and Jonathan Whetstine, PhD (Fox Chase Cancer Center) who discussed Epigenetics, and how drugs that require gene expression ("epigenetics drugs") are a viable s...